Inclusion Criteria:

          -  Existence of archival or fresh biopsy for FGFR testing

          -  FGFR testing of patients will be performed at the investigators' discretion up to a
             max. of 90 days prior to start of screening.

        Investigators should ensure all patients will be eligible in terms of disease status and
        lines of treatment within this timeframe.

          -  Documented urothelial carcinoma (transitional cell carcinoma) including urinary
             bladder, renal pelvis, ureters, urethra meeting all of the following criteria

               -  Histologically or cytologically confirmed (patients with mixed histologies are
                  required to have a dominant transitional cell pattern.)

               -  Locally advanced (T4b, any N; or any T, N 2−3) or metastatic disease (any T, any
                  N and M1). Locally advanced bladder cancer must be unresectable i.e. invading the
                  pelvic or abdominal wall (stage T4b) or presenting with bulky nodal disease
                  (N2-3).

          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 or 1

          -  Disease progression during or following treatment with at least one
             platinum-containing regimen (patients should have been treated for at least 2 cycles).
             In patients who received prior adjuvant/neoadjuvant platinum-containing chemotherapy,
             progression had to occur within 12 months of treatment.

          -  High FGFR1 or 3 mRNA (Messenger ribonucleic acid) expression levels (RNAscope score of
             3+ or 4+; measurement is part of this protocol) in archival or fresh Tumor biopsy
             specimen

          -  At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors
             (RECIST v.1.1) in contrast enhanced (unless contraindicated) CT or MRI

        Exclusion Criteria:

          -  Previous or concurrent cancer except

               -  cervical carcinoma in situ

               -  treated basal-cell or squamous cell skin carcinoma

               -  any cancer curatively treated > 3 years before randomization

               -  Curatively treated incidental prostate cancer (T1/T2a)

          -  Ongoing or previous anti-cancer treatment within 4 weeks before randomization.

          -  More than two prior lines of systemic anti-cancer therapy for urothelial carcinoma

          -  Ongoing or previous treatment with anti-FGFR directed therapies (e.g. receptor
             tyrosine kinase inhibitors including rogaratinib or FGFRspecific antibodies) or with
             taxanes or vinflunine

          -  Unresolved toxicity higher than National Cancer Institute's Common Terminology
             Criteria for Adverse Events, version 4.03 (CTCAE v.4.03) Grade 1 attributed to any
             prior therapy/procedure excluding alopecia, anemia and/or hypothyroidism

          -  History or current condition of an uncontrolled cardiovascular disease including any
             of the following conditions:

               -  Congestive heart failure (CHF) NYHA (New York Heart Association) > Class 2

               -  Unstable angina (symptoms of angina at rest) or new-onset angina (within last 3
                  months before randomization)

               -  Myocardial infarction (MI) within past 6 months before randomization

               -  Unstable cardiac arrhythmias requiring anti-arrhythmic therapy. Patients with
                  arrhythmia under control with anti-arrhythmic therapy such as beta-blockers or
                  digoxin are eligible.

          -  Arterial or venous thrombotic events or embolic events such as cerebrovascular
             accident (including transient ischemic attacks), deep vein thrombosis or pulmonary
             embolism within 3 months before randomization

          -  Current evidence of endocrine alteration of calcium Phosphate homeostasis (e.g.
             parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis,
             paraneoplastic hypercalcemia)

          -  Any hemorrhage / bleeding event ≥ CTCAE v.4.03 Grade 3 within 4 weeks before
             randomization

          -  Current diagnosis of any retinal detachment, retinal pigment epithelial detachment
             (RPED), serous retinopathy or retinal vein occlusion